Lisata Therapeutics (LSTA) - Earnings growth forecast for next year

Brandmark of Lisata Therapeutics (LSTA)

Lisata Therapeutics (LSTA) is developing its L CendR oncology platform through strategic partnerships, creating synergy in tumor therapy. Environmental responsibility obliges the company to optimize resources during clinical trials. The earnings per share (EPS) forecast for the coming year visualizes these expectations, where the 0.00 level captures the latest values. Capital efficiency is ensured by delegating research to international CRO networks, eliminating dependence on a single provider.

LSTA - Lisata Therapeutics Inc. Projected earnings per share increase next year over the range 04/28/2023 - 11/16/2026

Metric breakdowns and analytics for Lisata (LSTA)

- price and consensus price forecast:
Fundamental company valuation:LSTA, Lisata Therapeutics Inc.
Core merchandise of Lisata Therapeutics Inc.

The indicator is calculated as the arithmetic mean of expert forecasts for the year-over-year change in earnings per share. This metric determines the market consensus regarding future returns, allowing for a comparison between the business's fundamental value and the current share price. For Lisata Therapeutics (LSTA), which invests in overcoming the stromal barrier of tumors, the projected EPS changes for next year reflect the market's confidence in the commercialization of its R&D platforms.